Compare Novo Nordisk A/S (NVO) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance

Novo Nordisk A/STrade

iShares 0 3 Month Treasury Bond ETFTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Novo Nordisk A/S trades at $45.04 (market cap $198.57B), while iShares 0 3 Month Treasury Bond ETF trades at $100.49. The key difference: Novo Nordisk A/S pays a 4.03% dividend while iShares 0 3 Month Treasury Bond ETF pays none, and iShares 0 3 Month Treasury Bond ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.

	NVO	SGOV
Market Cap	$198.57B	—
Sector	Health	Fixed Income
52-Week High	$63.98	$100.72
52-Week Low	$35.29	$100.28
Enterprise Value	$213.37B	—
Dividend Yield	4.03%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.

The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.

iShares 0 3 Month Treasury Bond ETF

SGOV trades at $100.475 with minimal daily movement, showing price stability amid bearish technical signals. The stock faces selling pressure with moving averages indicating downward momentum, while oscillators remain neutral. Recent dividend activity shows consistent payouts, though key financial ratios remain unavailable for fundamental assessment.

The outlook remains cautious given the bearish technical setup and lack of fundamental data visibility. Investment opportunities appear limited without clear earnings metrics, while risks include continued technical weakness and market volatility affecting price stability. Investors require updated financial disclosures for proper valuation assessment.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVO

Canada imposes retaliatory tariffs on $20B of U.S. goods, escalating trade tensions and impacting North American supply chains.Seeking Alpha · 2 days agoNeutral 4-Factor Dividend Growth Strategy slightly outperforms SCHD with 14.89% returns, testing new variants.Seeking Alpha · 3 days agoBullish View details →

SGOV

Norway's sovereign fund plans to sell $80B in long-term U.S. Treasuries, raising concerns for TLT ETF holders.24/7 Wall Street · 2 days agoBearish View details →

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

About iShares 0 3 Month Treasury Bond ETF

SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.